On June 13, 2025, Cartesian Therapeutics, Inc. held its Annual Meeting where shareholders elected three directors, approved executive compensation, and ratified Ernst & Young as auditors, with 84.31% of shares represented. The voting reflected support for management's proposals with significant majorities in favor.